H MG-CoA reductase inhibitors (statins) are the most prescribed class of drugs in the world and significantly improve survival in patients with cardiovascular disease (1, 2) . In addition to decreasing low-density lipoproteins, statins have diverse pharmacologic effects, including anti-inflammatory and antithrombotic properties (3) . These effects have prompted speculation that statins may be useful in the treatment or prevention of severe sepsis (4), a syndrome defined as acute organ dysfunction secondary to infection and characterized by dysregulation of inflammation, coagulation, and other acute phase responses, yet this speculation is also tempered by the very real possibility of increased serious side effects that might occur with more frequent use of statins in acutely ill subjects (5) .
A variety of observational studies have examined the role of statins in the prevention or treatment of infection and sepsis, as recently reviewed (6 -11) . Most suggest a clinical benefit for statins, yet others show no benefit and one shows possible harm. None of these has examined potential mechanisms of benefit. Furthermore, like all observation-based pharmacoepidemiologic studies, these studies are susceptible to a number of confounders and biases analogous to studies of hormone replacement therapy (12) . Indeed, any "benefit" of statins on outcomes of infection may be the result of these and other biases (7, 13) .
Several randomized trials of statins in infection are planned, underway, or recently completed (5, 14 -24) . Unfortunately, these are small studies that are underpowered to address mortality or other clinically meaningful end points. Thus, there remains an unmet need to better understand what, if any, clinical benefit statins may have after appropriate consideration of confounders and biases. Of equal importance is the need to better understand the influence of statins on potential pathophysiological mechanisms. We examined the association of statin use with clinical outcomes and measures of inflammation, coagulation, and lymphocyte cell surface protein expression in a large, multicenter inception cohort study, Genetic and Inflammatory Markers of Sepsis (GenIMS). GenIMS was specifically designed to explore risk factors, including statin use, for the development and progression of severe sepsis and death in patients hospitalized with community-acquired pneumonia (CAP), the most common cause of severe sepsis. Our a priori hypotheses were that statin use would be associated with decreased rates of severe sepsis and death, reduced dysregulation of plasma markers of inflammation and coagulation, and changes in lymphocyte cell surface protein expression but that some of these differences would be explained by patient characteristics, illness severity, indication bias, and healthy user effects.
MATERIALS AND METHODS
Subjects. GenIMS enrolled subjects in the emergency departments of 28 hospitals in Pennsylvania, Connecticut, Michigan, and Tennessee from December 2001 to November 2003. Details of the study design, eligibility criteria, and clinical definitions have been published elsewhere (25) (26) (27) (28) (29) . Briefly, we enrolled subjects Ͼ18 yrs old who had a clinical and radiologic diagnosis of pneumonia per criteria of the study by Fine et al (30) and provided informed consent directly or by proxy. The study was approved by the institutional review boards of all sites.
Clinical Definitions and Outcome Variables. We ascertained comorbid conditions using the Charlson comorbidity index (31) and severity of illness using Acute Physiology and Chronic Health Evaluation III (32) and the Pneumonia Severity Index (30) . We defined severe sepsis as pneumonia plus acute organ dysfunction following the 2001 International Consensus Criteria (33) . We defined acute organ dysfunction as a new Sequential Organ Failure Assessment (34) score of Ն3 in any of six organ systems based on the recent international Sepsis Occurrence in the Acutely ill Patient study (35) . The initial empiric antibiotics received during the first 24 hrs of hospitalization were considered adequate if compliant with the 2001 American Thoracic Society Guidelines for the Management of Adults with Community-acquired Pneumonia (36) , which were in place at the time of the study. We determined survival postdischarge by telephone and National Death Index search. We used 90-day mortality as our primary measure of survival based on end point recommendations for sepsis trials from two recent international expert panels (37, 38) .
Statin Cohorts. Our approach consisted of two different comparison cohorts, each reflecting methods used in prior publications in this area. We first compared subjects with prior statin use (prior use cohort), defined as a history of statin use in the week before admission, with those with no prior use. We then compared prior statin users whose statins were continued inhospital (continued use cohort) with those with either no prior use or no inhospital use.
Laboratory Procedures. Blood was drawn for biomarker assays at emergency department presentation and daily for the first week. Generally, day 1 blood samples were drawn at enrollment and subsequent samples were drawn at 8 AM. For logistic reasons, we did not obtain day 1 samples from subjects presenting after 11 PM or on weekends and holidays. We assessed inflammation on days 1-7 in 1,886 (99.5%) subjects by measuring plasma tumor necrosis factor, interleukin-6, and interleukin-10 levels. We assessed plasma coagulation markers (D-dimer, plasminogen activator inhibitor, antithrombin, factor IX, and thrombin-antithrombin complex) on days 1-7 in the first 939 subjects (49.6%) enrolled using a commercial laboratory (Essoterix, Agoura Hills, CA). To determine whether statin users and nonusers were equally likely to have bacterial infection, we measured plasma procalcitonin levels and compared the proportion of subjects across different statin groups stratified by procalcitonin levels (Ͻ0.1, 0.1-0.25, 0.25-0.5, Ͼ0.5 ng/mL). We assessed day 1 lymphocyte cell surface marker expression using an automated fluorescence-activated cell sorter (FACSVantage SE; Becton Dickinson, Los Angeles, CA), which included CD3, CD4, CD5, CD 8, CD14, CD19, CD64, CD120a, CD120b, HLA-DR, TLR2, and TLR4. We analyzed these markers in a subset of 597 (31.5%) subjects enrolled in hospitals located within 60 miles of the University of Pittsburgh because samples for cell surface markers had to be analyzed within 48 hrs. Details of assay methodology for these markers have been described previously (25, 39) .
Statistical Analyses. Analyses were performed using SAS 8.2 (SAS Institute, Cary, NC) and SPSS 12.0 (SPSS Inc, Chicago, IL) and assuming statistical significance at p Ͻ .05. No corrections were made for multiple comparisons. We conducted univariate comparisons using Fisher's exact tests and t test or nonparametric counterparts as appropriate. We tested for differences in inflammatory and coagulation markers by transforming values to their natural log scale. We used Tobit models (40) when Ͼ5% values fell below detection thresholds and mixed models for repeated measures (41, 42) to determine changes in marker concentrations over time. We tested for differences in day 1 lymphocyte cell surface protein expression using two-sample t tests with a false discovery rate method to adjust for the multiple testing. We used multivariable models to compare severe sepsis rates and mortality between groups adjusting for potential confounders and accounting for clustering within specific hospitals by fitting the multivariable models using generalized estimating equations (43) . Four categories of potential confounders were eligible for inclusion in the multivariable models: demographics and comorbidities (age, race, gender, admitted from nursing home, comorbid illnesses, Charlson comorbidity); severity of illness (Pneumonia Severity Index [30] , Acute Physiology and Chronic Health Evaluation III Acute Physiology Score [32] , and Sequential Organ Failure Assessment score); treatments received (prehospital antibiotic use, adequacy of initial hospital antibiotics [36] , inpatient corticosteroid use); and healthy user indicators (insured, lives at home, functional status, former smoker, influenza and pneumovax vaccinations). Variables were entered into each model sequentially using forward stepwise regression while examining several potential models at each step. Variables were retained in the model based on a significance level of p Ͻ .05. To account for differential likelihood of receiving a statin, we constructed a propensity score for either prior or continued statin use (44) . This score included age, diabetes and cardiac disease, aspirin and anticoagulant use, functional status, and living arrangement before hospitalization.
RESULTS
Baseline Characteristics. We enrolled 2,320 subjects, excluding 288 (12%) discharged from the emergency department and 137 (6%) because their treating physicians subsequently excluded pneumonia as the cause of their illness (Fig. 1) . Thus, the final inpatient analysis cohort was 1895. Four hundred twenty-six (22.5%) were taking statins within the 7 days before admission (prior statin users), 354 (76.1%) of which had their statin continued inhospital (continued statin users). Table 1 describes the baseline characteristics of the prior and continued statin use groups. As expected, both prior and continued statin users were older with greater comorbidity, including a more frequent history of cardiovascular disease and diabetes, as compared with statin nonusers. Statin subjects were also less likely to be admitted from a nursing home and more likely to be white and to have higher Pneumonia Severity Index scores on presentation, although this latter difference was the result of a difference in age. There were no differences in severity of illness (Acute Physiology and Chronic Health Evaluation III, Acute Physiology Score), degree of organ dysfunction (Sequential Organ Failure Assessment), treatments administered, or admission to an intensive care unit. Statin users had a greater likelihood of being a healthy user with higher rates of insurance, living at home, good functional status, receipt of vaccinations, daily aspirin use, and having quit smoking. Among prior statin users, atorvastatin and simvastatin were used most commonly, accounting for 47.7% and 39.4% of subjects, whereas pravastatin (7.7%), lovastatin (3.5%), and fluvastatin (1.6%) were used less frequently. 
Clinical Outcomes. There were 582 (30.7%) subjects who developed severe sepsis, most commonly (47.1%) on day 1. In univariate analysis, there were no difference in severe sepsis rates between statin users and nonusers either for prior (30.8% vs. 30.7%, p ϭ .98) or continued use (30.2% vs. 30.8%, p ϭ .85). After adjusting for baseline characteristics, neither prior nor continued statin use appeared to protect against the development of severe sepsis regardless of whether propensity for statin use was included (Table 3 , prior use and continued use). These findings persisted even when excluding severity of illness measures, which overlap with the diagnostic criteria for severe sepsis, from the models.
Unadjusted 90-day mortality was lower in statin users, although this difference was only significant for continued statin use (7.9% vs. 12.1%, p ϭ .02) as opposed to prior use (9.2% vs. 12.0%, p ϭ .11). Interestingly, prior statin users whose statin was not continued inhospital had nearly twice the mortality of those whose statin was continued (15.3% vs. 7.9%, p ϭ .048) but similar rates of severe sepsis (33.3% vs. 30.2%, p ϭ .60). The final multivariable models of 90-day mortality with and without propensity adjustment are shown in Table 4 Biomarkers. In the entire cohort, higher circulating interleukin-6 levels and lower antithrombin activity correlated with overall mortality. Both prior and continued statin subjects had higher antithrombin activity over hospital days 1-7 (p ϭ .001 and p ϭ .006, respectively) compared with those without prior or continued statin use (Fig. 2) . However, the magnitude of the antithrombin differences was modest, typically Ͻ5% absolute difference in antithrombin activity. For instance, on day 1, mean (SD) antithrombin activity was 90.1% (17.1%) vs. 87.0% (18.4%) in those with prior as opposed to no prior statin use, whereas Ͼ60% activity is considered normal. There were no differences between the two groups in the other coagulation markers (D-dimer, factor IX, plasminogen activator inhibitor, thrombin-antithrombin complexes); in the inflammatory markers (interleukin-6, interleukin-10, tumor necrosis factor) (Fig. 3) ; or in day 1 expression of lymphocyte cell surface proteins (CD3, CD4, CD5, CD8, CD14, CD19, CD64, CD120a, CD 120b, HLA-DR, TLR2, TLR4) (data not shown).
DISCUSSION
In a large, prospective, multicenter cohort of patients hospitalized with CAP, we found no evidence of a protective effect for either prior or continued statin use on the development of severe sepsis. Prior statin use did not protect against 90-day mortality, whereas continued use showed only a marginal benefit, which was no longer evident after accounting for likelihood of being a statin user. Furthermore, we found only modest differences in a single plasma marker of coagulation, antithrombin, with no observed differences for any of the other markers of coagulation, inflammation, or lymphocyte cell surface protein expression. Although we found no significant evidence of benefit for statins use and mortality, the adjusted ORs were all in favor of the drugs. This leaves open the possibility of a small yet clinically meaningful benefit for statins in CAP, one which is likely smaller than prior studies suggest, with implications for powering future randomized trials.
Why have we failed to demonstrate a benefit for statins in which the majority of previous studies have shown benefit? The answer, we believe, lies in limitations of prior studies and our handling of potential sources of bias and confounding. We used detailed, prospectively collected information about baseline medical conditions, severity of illness, and treatments received such as adequacy of initial antibiotic therapy. Such granularity is uncommon in previous statin studies, especially those based on administrative data. The healthy user effect occurs when adherence to a treatment is a surrogate marker for engaging in a broad spectrum of health-promoting behaviors that are themselves linked to the outcome of interest. Indeed, statin users in our study were universally more likely to have healthy user indicators such as being insured, living at home, being of good functional status, receiving of vaccinations, taking daily aspirin, and quitting smoking, findings that are supported by other work in this area (13, (45) (46) (47) and likely to positively influence mortality in CAP (13) .
Indication bias can be seen when the choice to use or continue a drug is driven by factors associated with outcome. Prior studies suggest that worse outcomes in subjects whose statins were discontinued supports protective effect of statin. However, for a medication that is taken chronically, the decision to continue the drug inhospital primarily comes down to how sick the patient is and whether they are able to take medications by mouth. In our study, subjects whose statins were discontinued were more than twice as likely as continued users to be mechanically ventilated. Medications taken for chronic disease are often withheld in mechanically ventilated patients who tend to have higher mortality. The inclusion of propensity for continued statin use in the mortality models universally moved the adjusted OR closer to unity and the p value toward greater degrees of insignificance.
Our study has many strengths. First, we used a prospective cohort design, specifically designed to explore risk factors, including statin use, for the development and progression of severe sepsis and death in CAP (42) . By focusing on CAP, our study was less vulnerable to spurious differences in case-mix, although limiting the study to CAP also limits generalizability of our findings to other infections. Second, we recruited subjects at multiple centers to study a large number of subjects and determine that our findings were consistent across centers, suggesting our findings are robust and likely generalizable to patients with CAP else- where. Third, unlike previous studies, we were able to assess circulating biochemical indices of the inflammatory and coagulation pathways and lymphocyte cell surface protein expression to understand potential mechanisms. We focused on these pathways because modulation of inflammation and coagulation has been most closely tied to improved outcome in sepsis (30, 43) . Our results suggest that statins modified the coagulation response to infection, albeit only slightly, but had no discernible effect on circulating inflammatory cytokines or immune cell surface protein expression. Further studies, presumably under the auspices of a randomized interventional trial of statin therapy, will be necessary to extend and confirm these preliminary observations. The key limitations of this study stem from its observational cohort design, which is hypothesis-generating and cannot prove cause and effect. Even so, findings from this study enhance our understanding of prior work in this area and provide robust estimates of statins' effects on both mechanisms and outcomes that may inform the design of future randomized trials. Our findings are potentially biased by failure to account for unmeasured differences in patient characteristics, yet we are unaware of any likely unmeasured confounders that would significantly alter our findings. Another limitation was that we could only explore the association of statins in general and was underpowered to determine differences with particular statin agents or doses. The number of subjects in whom statins were discontinued after hospitalization was small and therefore, we cannot draw inferences about effect of discontinuation of statin therapy. Finally, we measured coagulation and cell surface markers in a subset. We were underpowered to detect small differences, although the clinical relevance of such findings would be unclear.
CONCLUSIONS
We found little to no evidence of a protective effect for statin use on meaningful clinical outcomes in CAP and a suggestion that healthy user effects and indication bias may be important elements to consider in any observational study of statin use in the setting of infection. Furthermore, the near complete absence of differences in coagulation, inflammation, and cell surface protein expression calls into question the use of Figure 2 . Mean coagulation factor levels over hospital days 1-7 in 939 subjects hospitalized with communityacquired pneumonia stratified by prior (left) and continued (right) statin use. Statin users had higher antithrombin levels over time as compared with those without statin use. There were no significant differences for any of the other coagulation factors. Means are geometric means estimated from Tobit models when appropriate. Geometric means roughly approximate medians. AT, antithrombin; PAI-1, plasminogen activator inhibitor-1; TAT, thrombin-antithrombin complex. Normal values are: D-dimer Յ256 ng/mL, TAT Յ5.0 ng/mL, PAI activity Յ31 IU/mL, factor IX activity Ն60%, and antithrombin activity Ն70%. Mean cytokine levels over hospital days 1-7 in 1886 subjects hospitalized with communityacquired pneumonia stratified by prior (left) and continued (right) statin use. There were no significant differences between groups for any of the measured cytokines. Means are geometric means estimated from Tobit models when appropriate. Geometric means roughly approximate medians. TNF, tumor necrosis factor; IL-6, interleukin-6; IL-10, interleukin-10. these measures as surrogate outcomes for any randomized controlled trial of statins in infection.
